Despite the wide availability of effective vaccines, COVID-19 continues to be an infectious
disease of global importance. Remdesivir is a broad-spectrum antiviral and was the first US …

COVID-19 is an infectious disease caused by a novel β-coronavirus, belonging to the same
subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an …

Remdesivir is an antiviral agent that has shown broad‐spectrum activity, including against
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clinical trials investigating …

In the years of Coronavirus Disease 2019 (COVID-19), various treatment options have been
utilized. COVID-19 continues to circulate in the global population, and the evolution of the …

Background In view of many unanswered clinical questions regarding treatment of COVID-
19 with remdesivir, we systematically identified, critically appraised and summarized the …

Background Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We
systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19 …

Remdesivir is a nucleoside antiviral recently studied in several randomized trials for
treatment of COVID-19. The available observational and prospective data are conflicting …

Objective We systematically reviewed the evidence of published original research to
determine the role of remdesivir in the management of patients with COVID-19 and a …

Background The nucleotide analogue prodrug remdesivir was among the first antiviral
therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a …

Background Remdesivir is considered to be a specific drug for treating coronavirus disease
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …